{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T23:02:40Z","timestamp":1793660560134,"version":"4.5.1"},"reference-count":45,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,4,16]],"date-time":"2022-04-16T00:00:00Z","timestamp":1650067200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy - Nucleic Acids"],"published-print":{"date-parts":[[2022,6]]},"DOI":"10.1016\/j.omtn.2022.04.010","type":"journal-article","created":{"date-parts":[[2022,4,18]],"date-time":"2022-04-18T02:30:26Z","timestamp":1650249026000},"page":"500-513","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":39,"special_numbering":"C","title":["Subcutaneous delivery of FGF21 mRNA therapy reverses obesity, insulin resistance, and hepatic steatosis in diet-induced obese mice"],"prefix":"10.1016","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2083-7807","authenticated-orcid":false,"given":"Stefano","family":"Bartesaghi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3231-2733","authenticated-orcid":false,"given":"Kristina","family":"Wallenius","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8861-4650","authenticated-orcid":false,"given":"Daniel","family":"Hovdal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathias","family":"Liljeblad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simonetta","family":"Wallin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niek","family":"Dekker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louise","family":"Barlind","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0679-3377","authenticated-orcid":false,"given":"Nigel","family":"Davies","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Seeliger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3125-4858","authenticated-orcid":false,"given":"Maria S\u00f6rhede","family":"Winzell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sima","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matt","family":"Theisen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis","family":"Brito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nils","family":"Bergenhem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7051-2189","authenticated-orcid":false,"given":"Shalini","family":"Andersson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-Rong","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.omtn.2022.04.010_bib1","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1038\/s41594-018-0054-4","article-title":"Tapping the RNA world for therapeutics","volume":"25","author":"Lieberman","year":"2018","journal-title":"Nat. Struct. Mol. Biol."},{"key":"10.1016\/j.omtn.2022.04.010_bib2","doi-asserted-by":"crossref","first-page":"20804","DOI":"10.1073\/pnas.1914673116","article-title":"Messenger RNA therapy as an option for treating metabolic disorders","volume":"116","author":"Chandler","year":"2019","journal-title":"Proc. Natl. Acad. Sci. U\u00a0S\u00a0A"},{"key":"10.1016\/j.omtn.2022.04.010_bib3","doi-asserted-by":"crossref","first-page":"119291","DOI":"10.1016\/j.biomaterials.2019.119291","article-title":"RNA delivery biomaterials for the treatment of genetic and rare diseases","volume":"217","author":"Zhao","year":"2019","journal-title":"Biomaterials"},{"key":"10.1016\/j.omtn.2022.04.010_bib4","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.smim.2017.08.015","article-title":"Delivering the right message: challenges and opportunities in lipid nanoparticles-mediated modified mRNA therapeutics-An innate immune system standpoint","volume":"34","author":"Granot","year":"2017","journal-title":"Semin. Immunol."},{"key":"10.1016\/j.omtn.2022.04.010_bib5","doi-asserted-by":"crossref","first-page":"eaaz6893","DOI":"10.1126\/sciadv.aaz6893","article-title":"Impact of mRNA chemistry and manufacturing process on innate immune activation","volume":"6","author":"Nelson","year":"2020","journal-title":"Sci. Adv."},{"key":"10.1016\/j.omtn.2022.04.010_bib6","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1038\/s41467-019-08852-4","article-title":"Intradermal delivery of modified mRNA encoding VEGF-A in patients with type 2 diabetes","volume":"10","author":"Gan","year":"2019","journal-title":"Nat. Commun."},{"key":"10.1016\/j.omtn.2022.04.010_bib7","doi-asserted-by":"crossref","first-page":"2265","DOI":"10.1021\/acs.molpharmaceut.8b01290","article-title":"Lipid nanoparticles for delivery of therapeutic RNA oligonucleotides","volume":"16","author":"Moss","year":"2019","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.omtn.2022.04.010_bib8","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1016\/j.ymthe.2019.02.012","article-title":"Delivering the messenger: advances in Technologies for therapeutic mRNA delivery","volume":"27","author":"Kowalski","year":"2019","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omtn.2022.04.010_bib9","doi-asserted-by":"crossref","first-page":"319","DOI":"10.4155\/tde-2016-0006","article-title":"mRNA vaccine delivery using lipid nanoparticles","volume":"7","author":"Reichmuth","year":"2016","journal-title":"Ther. Deliv."},{"key":"10.1016\/j.omtn.2022.04.010_bib10","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1038\/gt.2016.46","article-title":"Therapeutic efficacy in a hemophilia B model using a biosynthetic mRNA liver depot system","volume":"23","author":"DeRosa","year":"2016","journal-title":"Gene Ther."},{"key":"10.1016\/j.omtn.2022.04.010_bib11","doi-asserted-by":"crossref","first-page":"3548","DOI":"10.1016\/j.celrep.2017.11.081","article-title":"Systemic messenger RNA therapy as a treatment for methylmalonic acidemia","volume":"21","author":"An","year":"2017","journal-title":"Cell Rep."},{"key":"10.1016\/j.omtn.2022.04.010_bib12","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.1038\/s41591-018-0199-z","article-title":"Systemic messenger RNA as an etiological treatment for acute intermittent porphyria","volume":"24","author":"Jiang","year":"2018","journal-title":"Nat. Med."},{"key":"10.1016\/j.omtn.2022.04.010_bib13","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1016\/j.omtn.2017.04.006","article-title":"Translation of angiotensin-converting enzyme 2 upon liver- and lung-targeted delivery of optimized chemically modified mRNA","volume":"7","author":"Schrom","year":"2017","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.omtn.2022.04.010_bib14","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1038\/mt.2012.250","article-title":"Systemic delivery of modified mRNA encoding herpes simplex virus 1 thymidine kinase for targeted cancer gene therapy","volume":"21","author":"Wang","year":"2013","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omtn.2022.04.010_bib15","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1716153","article-title":"Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis","volume":"379","author":"Adams","year":"2018","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.omtn.2022.04.010_bib16","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.omtn.2019.01.013","article-title":"Optimization of lipid nanoparticles for intramuscular administration of mRNA vaccines","volume":"15","author":"Hassett","year":"2019","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.omtn.2022.04.010_bib17","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1056\/NEJMoa2035389","article-title":"Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine","volume":"384","author":"Baden","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.omtn.2022.04.010_bib18","unstructured":"PubChem [Internet]. Bethesda (MD): National Library of Medicine (US), National Center for Biotechnology Information; 2004-. PubChem Patent Summary for US-9738593-B2; Available from: https:\/\/pubchem.ncbi.nlm.nih.gov\/patent\/US-9738593-B2."},{"key":"10.1016\/j.omtn.2022.04.010_bib19","doi-asserted-by":"crossref","first-page":"2439","DOI":"10.1056\/NEJMoa2027906","article-title":"Safety and immunogenicity of two RNA-based covid-19 vaccine candidates","volume":"383","author":"Walsh","year":"2020","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.omtn.2022.04.010_bib20","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.omtn.2021.03.008","article-title":"Functionalized lipid nanoparticles for subcutaneous administration of mRNA to achieve systemic exposures of a therapeutic protein","volume":"24","author":"Davies","year":"2021","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.omtn.2022.04.010_bib21","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1016\/j.ymthe.2018.03.010","article-title":"A novel amino lipid series for mRNA delivery: improved endosomal escape and sustained pharmacology and safety in non-human primates","volume":"26","author":"Sabnis","year":"2018","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omtn.2022.04.010_bib22","doi-asserted-by":"crossref","first-page":"107","DOI":"10.2991\/jegh.k.191028.001","article-title":"Epidemiology of type 2 diabetes - global burden of disease and forecasted trends","volume":"10","author":"Khan","year":"2019","journal-title":"J.\u00a0Epidemiol. Glob. Health"},{"key":"10.1016\/j.omtn.2022.04.010_bib23","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.cmet.2019.01.004","article-title":"A dozen years of Discovery: insights into the physiology and pharmacology of FGF21","volume":"29","author":"Kliewer","year":"2019","journal-title":"Cell Metab."},{"key":"10.1016\/j.omtn.2022.04.010_bib24","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1038\/s41574-020-0386-0","article-title":"The therapeutic potential of FGF21 in metabolic diseases: from bench to clinic","volume":"16","author":"Geng","year":"2020","journal-title":"Nat. Rev. Endocrinol."},{"key":"10.1016\/j.omtn.2022.04.010_bib25","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.celrep.2016.08.086","article-title":"mTORC1 is a major regulatory node in the FGF21 signaling network in adipocytes","volume":"17","author":"Minard","year":"2016","journal-title":"Cell Rep."},{"key":"10.1016\/j.omtn.2022.04.010_bib26","doi-asserted-by":"crossref","first-page":"2050","DOI":"10.1210\/me.2010-0142","article-title":"Research resource: comprehensive expression atlas of the fibroblast growth factor system in adult mouse","volume":"24","author":"Fon Tacer","year":"2010","journal-title":"Mol. Endocrinol."},{"key":"10.1016\/j.omtn.2022.04.010_bib27","doi-asserted-by":"crossref","first-page":"e49345","DOI":"10.1371\/journal.pone.0049345","article-title":"Rationale-based engineering of a potent long-acting FGF21 analog for the treatment of type 2 diabetes","volume":"7","author":"Hecht","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.omtn.2022.04.010_bib28","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.cmet.2013.08.005","article-title":"The effects of LY2405319, an FGF21 analog, in obese human subjects with type 2 diabetes","volume":"18","author":"Gaich","year":"2013","journal-title":"Cell Metab."},{"key":"10.1016\/j.omtn.2022.04.010_bib29","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1002\/hep.20701","article-title":"Design and validation of a histological scoring system for nonalcoholic fatty liver disease","volume":"41","author":"Kleiner","year":"2005","journal-title":"Hepatology"},{"key":"10.1016\/j.omtn.2022.04.010_bib30","series-title":"Translational Research Methods in Diabetes, Obesity, and Nonalcoholic Fatty Liver Disease","article-title":"Animal models of type 2 diabetes, obesity and nonalcoholic steatohepatitis \u2013 clinical translatability and applicability in preclinical drug development","author":"Hansen","year":"2019"},{"key":"10.1016\/j.omtn.2022.04.010_bib31","doi-asserted-by":"crossref","first-page":"113","DOI":"10.12688\/f1000research.9970.1","article-title":"Recent advances in (therapeutic protein) drug development","volume":"6","author":"Lagass\u00e9","year":"2017","journal-title":"F1000Res."},{"key":"10.1016\/j.omtn.2022.04.010_bib32","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1038\/nrd.2017.243","article-title":"mRNA vaccines - a new era in vaccinology","volume":"17","author":"Pardi","year":"2018","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.omtn.2022.04.010_bib33","series-title":"Pfizer-BioNTech COVID-19 Vaccine","article-title":"FDA takes key action in fight against COVID-19 By issuing emergency use authorization for first COVID-19 vaccine","year":"2020"},{"key":"10.1016\/j.omtn.2022.04.010_bib34","series-title":"Moderna COVID-19 Vaccine","article-title":"FDA takes additional action in fight against COVID-19 By issuing emergency use authorization for second COVID-19 vaccine","year":"2020"},{"key":"10.1016\/j.omtn.2022.04.010_bib35","series-title":"EMA Recommends First COVID-19 Vaccine for Authorisation in the EU","author":"Agency","year":"2020"},{"key":"10.1016\/j.omtn.2022.04.010_bib36","series-title":"EMA Recommends COVID-19 Vaccine Moderna for Authorisation in the EU","author":"Agency","year":"2020"},{"key":"10.1016\/j.omtn.2022.04.010_bib37","doi-asserted-by":"crossref","first-page":"4493","DOI":"10.1038\/s41467-018-06936-1","article-title":"Cell specific delivery of modified mRNA expressing therapeutic proteins to leukocytes","volume":"9","author":"Veiga","year":"2018","journal-title":"Nat. Commun."},{"key":"10.1016\/j.omtn.2022.04.010_bib38","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1093\/cvr\/cvab076","article-title":"Pharmacological treatment with FGF21 strongly improves plasma cholesterol metabolism to reduce atherosclerosis","volume":"118","author":"Liu","year":"2021","journal-title":"Cardiovasc. Res."},{"key":"10.1016\/j.omtn.2022.04.010_bib39","doi-asserted-by":"crossref","first-page":"250","DOI":"10.2337\/db08-0392","article-title":"Fibroblast growth factor 21 reverses hepatic steatosis, increases energy expenditure, and improves insulin sensitivity in diet-induced obese mice","volume":"58","author":"Xu","year":"2009","journal-title":"Diabetes"},{"key":"10.1016\/j.omtn.2022.04.010_bib40","doi-asserted-by":"crossref","first-page":"6018","DOI":"10.1210\/en.2008-0816","article-title":"Fibroblast growth factor 21 corrects obesity in mice","volume":"149","author":"Coskun","year":"2008","journal-title":"Endocrinology"},{"key":"10.1016\/j.omtn.2022.04.010_bib41","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1016\/j.ebiom.2015.05.028","article-title":"Sustained Brown fat stimulation and insulin sensitization by a humanized bispecific antibody agonist for fibroblast growth factor receptor 1\/\u03b2Klotho complex","volume":"2","author":"Kolumam","year":"2015","journal-title":"EBioMedicine"},{"key":"10.1016\/j.omtn.2022.04.010_bib42","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1172\/JCI23606","article-title":"FGF-21 as a novel metabolic regulator","volume":"115","author":"Kharitonenkov","year":"2005","journal-title":"J.\u00a0Clin. Invest."},{"key":"10.1016\/j.omtn.2022.04.010_bib43","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1530\/EC-20-0152","article-title":"FGF21 regulates hepatic metabolic pathways to improve steatosis and inflammation","volume":"9","author":"Keinicke","year":"2020","journal-title":"Endocr. Connect."},{"key":"10.1016\/j.omtn.2022.04.010_bib44","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1210\/me.2014-1295","article-title":"Thermogenic activity of UCP1 in human white fat-derived beige adipocytes","volume":"29","author":"Bartesaghi","year":"2015","journal-title":"Mol. Endocrinol."},{"key":"10.1016\/j.omtn.2022.04.010_bib45","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/j.omtm.2018.04.003","article-title":"Biocompatible, purified VEGF-A mRNA improves cardiac function after intracardiac injection 1 Week post-myocardial infarction in swine","volume":"9","author":"Carlsson","year":"2018","journal-title":"Mol. Ther. Methods Clin. Dev."}],"container-title":["Molecular Therapy - Nucleic Acids"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2162253122000865?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2162253122000865?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T01:31:44Z","timestamp":1761874304000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2162253122000865"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6]]},"references-count":45,"alternative-id":["S2162253122000865"],"URL":"https:\/\/doi.org\/10.1016\/j.omtn.2022.04.010","relation":{},"ISSN":["2162-2531"],"issn-type":[{"value":"2162-2531","type":"print"}],"subject":[],"published":{"date-parts":[[2022,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Subcutaneous delivery of FGF21 mRNA therapy reverses obesity, insulin resistance, and hepatic steatosis in diet-induced obese mice","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy - Nucleic Acids","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.omtn.2022.04.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors.","name":"copyright","label":"Copyright"}]}}